openPR Logo
Press release

B-cell Maturation Antigen (BCMA) Targeted Therapies Market 2021 : by Product Type, by Indication, and by Geography Celgene Corporation, GlaxoSmithKline plc., Novartis AG

05-27-2021 08:56 AM CET | Health & Medicine

Press release from: Coherent Market Insights

B-cell Maturation Antigen (BCMA)

B-cell Maturation Antigen (BCMA)

Recurrence of multiple myeloma has been a highly prevalent health condition, which requires novel and effective immunotherapeutic treatment. According to Leukemia Research by Elsevier, as of 2014, the incidence of multiple myeloma is estimated to be around 120,000 cases per year, with a global prevalence of over one million cases.

B-cell maturation antigen (BCMA), is a cell surface protein that is expressed on the malignant plasma cells. This cell surface protein has emerged as a very selective antigen targeted therapy for the treatment of multiple myeloma. BCMA targeted therapies actively involve three major types of immunotherapies on the basis of product class namely, chimeric antigen receptor T-cells (CAR T Cells), bispecific antibodies, and antibody drug conjugates (ADCs). These advanced therapies are expected to improve the survival rate of multiple myeloma patients.

Request PDF Brochure of this report:
https://www.coherentmarketinsights.com/insight/request-pdf/190

Market Dynamics

Increasing prevalence of multiple myeloma is expected to favor the B-cell maturation antigen (BCMA) targeted therapies market worldwide. According to the American Cancer Society, U.S., in 2016, the lifetime risk for multiple myeloma was around 1 in 143 people, with an estimated 30,280 adults (17,490 men and 12,790 women) diagnosed with multiple myeloma. The mortality rate of the disease was estimated to be 12,590 (6,660 men and 5,930 women) in 2016.

Key players are actively involved in the development of immunotherapies targeting BCMA for the treatment of multiple myeloma, the demand for which is expected to increase, This in turn, is expected to boost development of novel treatments for relapsed or refractory myeloma. Furthermore, patients undergoing existing drug therapies are prone to the risk of relapse. Hence, B-cell maturation antigen targeted therapy, which primarily addresses this concern is expected to gain rapid traction.

Increasing number of BCMA targeted therapies in pipeline and increasing prevalence of multiple myeloma are expected to favor growth of the B-cell maturation antigen (BCMA) targeted therapies market worldwide. Increasing recurrence of multiple myeloma has been a major obstacle. According to the National Cancer Institute, in 2016, around 75,000 patients globally were recorded to be suffering from relapsed or refractory multiple myeloma, with a relative survival rate of 5 years. According to American Cancer Society, as of 2017, around 30,280 multiple myeloma cases are estimated to be diagnosed, out of which around 12,590 deaths are estimated to occur. Multiple myeloma (MM) is the second most common hematological malignancy in the U.S. and European countries.

Request Here Sample Report:
https://www.coherentmarketinsights.com/insight/request-sample/190

According to American Cancer Society, in the U.S. the lifetime risk of contracting multiple myeloma is 1 in 143 (0.7%). B-cell maturation antigen (BCMA), is a cell surface protein that is expressed on the malignant plasma cells. This cell surface protein has emerged as a very selective antigen to be targeted for the treatment of multiple myeloma.

B-cell maturation antigen possess co-immunoprecipitation property with a master transcription factor (IRF-4) are mediated for myeloma cell survival. This suggests the potential effect of BCMA in oncogenesis, making it a choice of preference for multiple myeloma treatment. Thus, rise in number of multiple myeloma cases and development of novel BCMA therapy for the treatment of multiple myeloma provides lucrative opportunities for the market players.

Some of the major players involved in the development of B-cell maturation antigen (BCMA) targeted therapies market are Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd.

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount for Buyers UPTO 30% OFF On Any Research Report

Buy Now with Discount for Premium Report 2021:
https://www.coherentmarketinsights.com/insight/buy-now/190

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release B-cell Maturation Antigen (BCMA) Targeted Therapies Market 2021 : by Product Type, by Indication, and by Geography Celgene Corporation, GlaxoSmithKline plc., Novartis AG here

News-ID: 2291804 • Views: 348

More Releases from Coherent Market Insights

How much is Airport Metal Detectors Market work in near Future?
Airport Metal Detectors Market Perspective 2021 𝗥𝗲𝗽𝗼𝗿𝘁 𝗣𝗮𝗴𝗲𝘀: [150 Pages] Airport metal detectors are sensitive to metals, including orthopedic metal implants inside your body. The most commonly implanted orthopedic materials include stainless steel, cobalt chrome, and titanium. As airport security measures have been heightened and metal detectors are more sophisticated, people who have metal parts face greater and more frequent inconvenience with more invasive security checks becoming commonplace. The use of…
How much is Roofing Systems Market work in near Future?
Roofing Systems Market Perspective 2021 𝗥𝗲𝗽𝗼𝗿𝘁 𝗣𝗮𝗴𝗲𝘀: [130 Pages] The roof of your house is an important part of what helps keep you and your family warm, dry, and safe. Known accurately as a roofing system, they can be made of asphalt, tar, rubber, clay, composite material, wood, metal, cement, or stone. A roof is the top covering of a building, including all materials and constructions necessary to support it…
[PDF] What segments are covered in Analog IC Market Report?
Analog IC Market Perspective 2021 𝗥𝗲𝗽𝗼𝗿𝘁 𝗣𝗮𝗴𝗲𝘀: [130 Pages] An analog integrated circuit (IC) is a basic component in most electronic devices, the most basic circuit that is a part of a larger electronic circuit. Analog circuits are circuits dealing with signals free to vary from zero to full power supply voltage. This stands in contrast to digital circuits, which almost exclusively employ “all or nothing” signals: voltages restricted to values…
[PDF] Welding Equipment Market Outlook, Top Competitors, Basic Principle, Applic …
𝗥𝗲𝗽𝗼𝗿𝘁 𝗣𝗮𝗴𝗲𝘀: [120 Pages] The welding equipment includes the welding machine, power supplies and devices directly used to conduct the welding process, jigs and fixtures for the rapid assembly of the parts to be welded, for holding the parts during welding, and for preventing or reducing warpage of the welded articles, auxiliary equipment used for transporting the parts during welding and for mounting and transporting the welding apparatus, and various other…

All 5 Releases


More Releases for BCMA

B-cell Maturation Antigen (BCMA) Targeted Therapies Market Strategies, Technolog …
Recurrence of multiple myeloma has been a highly prevalent health condition, which requires novel and effective immunotherapeutic treatment. According to Leukemia Research by Elsevier, as of 2014, the incidence of multiple myeloma is estimated to be around 120,000 cases per year, with a global prevalence of over one million cases. B-cell maturation antigen (BCMA), is a cell surface protein that is expressed on the malignant plasma cells. This cell surface…
B-cell Maturation Antigen (BCMA) Targeted Therapies Market - Insights, Size, Ana …
The Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by product type (CAR-T cell, bispecific antibodies, and antibody drug conjugates), and by indication (acute lymphoblastic leukemia, and multiple myeloma) has potential products in pipeline, as highlighted in a new report published by Coherent Market Insights. Increasing number of BCMA targeted therapies in pipeline and increasing prevalence of multiple myeloma are expected to favor growth of the B-cell maturation antigen (BCMA)…
B-cell Maturation Antigen (BCMA) Targeted Therapies Market Growth, Analysis, and …
The Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by product type (CAR-T cell, bispecific antibodies, and antibody drug conjugates), and by indication (acute lymphoblastic leukemia, and multiple myeloma) has potential products in pipeline, as highlighted in a new report published by Coherent Market Insights. Increasing number of BCMA targeted therapies in pipeline and increasing prevalence of multiple myeloma are expected to favor growth of the B-cell maturation antigen (BCMA)…
B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, Ind …
The Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by product type (CAR-T cell, bispecific antibodies, and antibody drug conjugates), and by indication (acute lymphoblastic leukemia, and multiple myeloma) has potential products in pipeline, as highlighted in a new report published by Coherent Market Insights. Increasing number of BCMA targeted therapies in pipeline and increasing prevalence of multiple myeloma are expected to favor growth of the B-cell maturation antigen (BCMA)…
B Cell Maturation Antigen (BCMA) Targeted Therapies Market Poised for Steady Gro …
B-cell maturation antigen (BCMA) is a protein, also called tumor necrosis factor receptor superfamily member 17 (TNFRSF17) or CD269 antigen, which is encoded in humans by TNFRSF17 gene. BCMA is an essential member of tumor necrosis factor receptor super family and is preferentially expressed in B lymphocytes. B-cell maturation antigen receptor is necessary for B-cell development and also in autoimmune response. This receptor specially binds to tumor necrosis factor (TNF)…
B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Global Industry Ins …
Multiple myeloma is an incurable disease of plasma cells, which needs some intervention by clinical researchers. However, there have been recent success in developing such therapy that can be effective in hematologic malignancies such as chimeric antigen receptor CAR-T cell therapy, which is expected to be promising in cancer treatment. However, researchers have found little success in finding a specific target antigen under CAR T-cell therapies for treating multiple myeloma.…